Sorrento Therapeutics (SRNE -0.6%) has signed a letter of intent to acquire Cambridge, MA-based SmartPharm Therapeutics, a developer of non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases.
The company plans to accelerate development of multiple candidates for in vivo gene-encoded expression of Sorrento antibodies, starting with COVID-19 “cure” STI-1499.
It says SmartPharm’s Gene Mab platform enables intramuscular delivery of low-immunogenic DNA plasmid encoded with a therapeutic antibody for long-lasting expression.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.